Industry News
Biotechnology Industry News
As obesity pioneer Novo Nordisk…
As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline. Novo has inked a multiyear research collaboration
Mere months after its cancer…
Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a reorganization that will see the oncology company’s Pennsylvania site wind down and 130 employees laid off,
Amylyx’s withdrawn-from-market…
Amylyx’s withdrawn-from-market Relyvrio has failed to make an impact on primary or secondary endpoints in a rare neurodegenerative disease, prompting the company to discontinue the program.
Wugen has raised $115 million,…
Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first off-the-shelf CAR-T for T-cell malignancies. A pivotal trial is underway, putting the company on track to
Nykode Therapeutics has designed a…
Nykode Therapeutics has designed a two-year plan to turn its fortunes around. Having lost a deal with Genentech—and with the future of a Regeneron pact uncertain—the Norwegian biotech is focusing on delivering phase 2 data
Right on the heels of a similar…
Right on the heels of a similar deal, Fosun Pharma has outlicensed a second inflammatory disease candidate to a Western biotech startup.
Eight months after Sanofi’s…
Eight months after Sanofi’s former Chief Medical Officer, Dietmar Berger, M.D., departed, the French drugmaker has selected a successor.
Regeneron has reported a phase 3…
Regeneron has reported a phase 3 win in generalized myasthenia gravis, positioning the biotech to file for FDA approval of its siRNA candidate in the increasingly competitive neuromuscular disease.
The National Cancer Institute is…
The National Cancer Institute is ending its support for a 26-year-old push to advance clinical trials for children with brain tumors.
Novartis is putting down $30…
Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new drug in the neurodegeneration space.
Another cell therapy biotech has…
Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. California CAR-T company Appia Bio has closed up shop, founding CEO JeenJoo “JJ” Kang, Ph.D., wrote in an Aug.
Eli Lilly reported that all three…
Eli Lilly reported that all three doses of its oral GLP-1 orforglipron helped patients who are obese or overweight with Type 2 diabetes achieve “significant” weight loss in a phase 3 trial. The drug also
Akeso is adding a pair of…
Akeso is adding a pair of late-stage wins to its scorecard in both ankylosing spondylitis and atopic dermatitis, while also teeing up a new drug submission for one of the candidates.
Amid a frozen-over IPO landscape,…
Amid a frozen-over IPO landscape, LB Pharmaceuticals has filed to go public to fund a pivotal schizophrenia study for its modification of an ex-Sanofi drug.
After a nearly month-long delay,…
After a nearly month-long delay, the Food and Drug Administration has approved the investigational new drug application for Coya Therapeutics’ amyotrophic lateral sclerosis asset. With the FDA’s go-ahead, Coya plans to launch a multicenter phase
Arnatar Therapeutics has unveiled…
Arnatar Therapeutics has unveiled with $52 million in series A financing to bankroll new RNA-based therapies, including a lead candidate that takes aim at a rare genetic disease called Alagille syndrome.
AbbVie has written the next…
AbbVie has written the next chapter in its epic quest to treat psychiatric disorders, agreeing to buy a psychedelic drug candidate from Gilgamesh Pharmaceuticals for up to $1.2 billion.
PDS Biotech has reported final…
PDS Biotech has reported final phase 2 data on PDS0101 in head and neck cancer, linking a combination of the immunotherapy and Keytruda to median overall survival of 39.3 months.
The Supreme Court is allowing the…
The Supreme Court is allowing the Trump administration to axe $783 million in federal research funding, reversing a lower court’s decision that required the National Institutes of Health to keep funding the terminated grants.
Arena BioWorks has laid off 30% of…
Arena BioWorks has laid off 30% of its workers 19 months after launching with $500 million and visions of bringing the Bell Labs model to biotech.